MRKR vs MTNB

Marker Therapeutics, Inc. vs Matinas Biopharma Holdings, Inc — Valuation Comparison 2026

MRKR

Biotechnology
Marker Therapeutics, Inc.
Quality
6.1
out of 10
Value Trap
18
SAFE
Price
$1.51
Last close
Models
9/13
Active
VS

MTNB

Biotechnology
Matinas Biopharma Holdings, Inc
Quality
4.0
out of 10
Value Trap
31
LOW
Price
$0.79
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MRKR Fair ValueMRKR Upside MTNB Fair ValueMTNB Upside
Bayesian DCF Intrinsic $0.89 -40.8% $0.47 -40.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.10 +39.1% $3.08 +287.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MRKR vs MTNB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MRKR vs MTNB — Which Stock Is More Undervalued?

MRKR scores higher with a 6.1/10 quality rating vs MTNB's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Marker Therapeutics, Inc. (MRKR) and Matinas Biopharma Holdings, Inc (MTNB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MRKR currently trades at $1.51 with a QOC of 6.1/10, while MTNB trades at $0.79 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).